We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Project Set to Develop Algorithm Able to Accurately Predict and Detect Sepsis

By LabMedica International staff writers
Posted on 18 Nov 2019
Print article
Image: The DxH 900 hematology analyzer (Photo courtesy of Beckman Coulter)
Image: The DxH 900 hematology analyzer (Photo courtesy of Beckman Coulter)
A large research contract has been signed that will enable the development and commercialization of a novel machine-learning-based sepsis detection algorithm.

Sepsis is caused by an inflammatory immune response triggered by an infection. It is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. Common signs and symptoms include fever, increased heart rate, increased breathing rate, and confusion. There may also be symptoms related to a specific infection, such as a cough with pneumonia, or painful urination with a kidney infection. In the very young, old, and people with a weakened immune system, there may be no symptoms of a specific infection and the body temperature may be low or normal, rather than high.

The 1.25 million USD contract (with potential expansion to an additional 6.5 million USD) from the [U.S.] Biomedical Advanced Research and Development Authority (BARDA) provides funds for Beckman Coulter, Inc. (Brea, CA, USA) in collaboration with Dascena, Inc. (Oakland, CA, USA) to develop and commercialize a novel machine-learning-based sepsis detection algorithm. BARDA is a U.S. Department of Health and Human Services office responsible for procurement and development of countermeasures principally against bioterrorism, but also including chemical, nuclear, and radiological threats as well as pandemic influenza and emerging diseases. More broadly if functions as an interface between the U.S. Government and the biomedical industry.

By combining novel laboratory test parameter values with electronic health record information, the objective of this project is the development of a next-generation analytic algorithm able to accurately predict and detect sepsis earlier. The project is set to integrate the novel laboratory parameters generated by the Beckman Coulter DxH 900 hematology analyzer into Dascena’s best-in-class sepsis prediction and detection algorithm.

The Beckman Coulter FDA-cleared Early Sepsis Indicator kit used with the DxH 900 Hematology Analyzer has already been shown to improve diagnosis of sepsis by 43% and, together with clinical signs and symptoms, to improve the ability to rule out sepsis by 63%. The Early Sepsis Indicator measures monocyte distribution width to support prompt clinical decision making. The next-generation analytic algorithm being developed by Dascena will be able to accurately predict and detect sepsis even earlier.

“Sepsis, defined as dysregulated immune response to infection, is a high-priority health concern accounting for the deaths of approximately 250,000 Americans and millions globally each year, and is the most expensive medical condition encountered in most hospitals,” said Dr. Elliott Crouser, professor of pulmonary, critical care, and sleep medicine at the Ohio State University Wexner Medical Center (Columbus, OH, USA), and principal investigator in the clinical trial for Beckman Coulter’s Early Sepsis Indicator. “Delays in the detection and treatment of sepsis during its early phases can contribute significantly to adverse outcomes. The objective of this project will be to deliver earlier and more accurate sepsis detection. The resulting predictive analytic algorithm for sepsis detection is expected to have a major global impact.”

Related Links:
Beckman Coulter, Inc.
Dascena, Inc.
Ohio State University Wexner Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.